Holen Sie sich die Stockscreener-App
28.76
4.63%
-1.3995
Schlusskurs vom Vortag:
$30.16
Offen:
$30.68
24-Stunden-Volumen:
284.75K
Relative Volume:
0.35
Marktkapitalisierung:
$1.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.06%
1M Leistung:
+12.10%
6M Leistung:
+126.32%
1J Leistung:
+40.11%
1-Tages-Spanne:
$28.67
$31.00
1-Wochen-Bereich:
$27.26
$31.00
52-Wochen-Spanne:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
99 HIGH STREET, BOSTON
Vergleichen Sie RAPP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
28.75 | 1.44B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-09-16 | Eingeleitet | Truist | Buy |
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-08 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Eingeleitet | Jefferies | Buy |
| 2024-07-02 | Eingeleitet | Stifel | Buy |
| 2024-07-02 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data - Investing.com UK
Rapport Therapeutics (NASDAQ:RAPP) Receives “Buy” Rating from BTIG Research - Defense World
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know - Yahoo Finance
Rapport Therapeutics (NASDAQ:RAPP) Earns Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge - Yahoo Finance
RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Yahoo Finance
Affinity Asset Advisors LLC Purchases Shares of 199,643 Rapport Therapeutics, Inc. $RAPP - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - Defense World
Wall Street Zen Downgrades Rapport Therapeutics (NASDAQ:RAPP) to Sell - MarketBeat
Rapport Therapeutics Announces New Data and Post Hoc - GlobeNewswire
Will Rapport Therapeutics Inc. stock see PE expansionJuly 2025 Momentum & Low Drawdown Momentum Trade Ideas - Newser
Is Rapport Therapeutics Inc. stock trading at a premium valuationWeekly Market Report & Weekly High Conviction Trade Ideas - Newser
(RAPP) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Rapport Therapeutics (RAPP) Stock Analysis Report | Financials & Insights - Benzinga
Rapport Therapeutics COO Cheryl Gault Sells 5,000 Shares - TradingView
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? - sharewise.com
Rapport Therapeutics (RAPP) Is Down 11.3% After Positive Phase 2a Data and $269M Offering – Has the Bull Case Changed? - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Shares Up 6.1%Here's What Happened - MarketBeat
A Look at Rapport Therapeutics’s Valuation as New RAP-219 Phase 2a Data Presentation Approaches - Sahm
How does Rapport Therapeutics Inc (RAPP) change from a tortoise to a hare? - Setenews
Could RAP-219’s Upcoming Data Reveal a Turning Point for Rapport Therapeutics’ Pipeline Strategy (RAPP)? - simplywall.st
Rapport Therapeutics to Present New Phase 2a Data Analysis - GlobeNewswire
What Analyst Ratings Reveal About Sagar Systech Limiteds Future ValueStock Buy Signals & Fast Growing Trading Plans - earlytimes.in
(RAPP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can Rapport Therapeutics Inc. stock outperform in 2025 bull marketStop Loss & Long-Term Growth Stock Strategies - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at BTIG Research - MarketBeat
Can trapped investors hope for a rebound in Rapport Therapeutics Inc. - newser.com
What institutional flow reveals about Rapport Therapeutics Inc.Weekly Stock Analysis & Daily Entry Point Trade Alerts - newser.com
Will Rapport Therapeutics Inc. stock pay special dividendsJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Analyzing Rapport Therapeutics Inc. with risk reward ratio chartsTreasury Yields & Safe Capital Growth Tips - newser.com
BTIG Research Initiates Coverage on Rapport Therapeutics With Buy Rating, $47 Price Target - MarketScreener
BTIG Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - Nasdaq
What candlestick patterns are forming on Rapport Therapeutics Inc.Gap Up & Verified Entry Point Signals - newser.com
Why Rapport Therapeutics Inc. stock is a value investor pick2025 Technical Overview & Technical Pattern Based Signals - newser.com
Published on: 2025-11-18 22:13:16 - newser.com
Tools to monitor Rapport Therapeutics Inc. recovery probabilityMarket Sentiment Report & High Accuracy Swing Entry Alerts - newser.com
Rapport Therapeutics Executives Sell Shares Under Trading Plans - TradingView
CEO Ceesay Sells 10,916 ($275K) Of Rapport Therapeutics Inc [RAPP] - TradingView
Rapport Therapeutics, Inc. (RAPP) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Does Rapport Therapeutics' Rising Losses and Improving Per-Share Results Reveal a Shift in RAPP's Strategy? - Sahm
Is Rapport Therapeutics Inc a good long term investmentHigh Yield Income Stocks & Predict Price Movements With AI Precision - earlytimes.in
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Es liegen keine Finanzdaten für Rapport Therapeutics Inc (RAPP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Rapport Therapeutics Inc-Aktie (RAPP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gault Cheryl | Chief Operating Officer |
Nov 26 '25 |
Sale |
30.10 |
5,000 |
150,486 |
171,928 |
| Ceesay Abraham | Chief Executive Officer |
Nov 17 '25 |
Sale |
25.19 |
5,833 |
146,931 |
573,746 |
| Ceesay Abraham | Chief Executive Officer |
Nov 17 '25 |
Sale |
25.20 |
5,083 |
128,116 |
35,978 |
| Bredt David | Chief Scientific Officer |
Nov 17 '25 |
Sale |
25.19 |
8,500 |
214,091 |
401,142 |
| Bredt David | Chief Scientific Officer |
Oct 15 '25 |
Sale |
25.79 |
8,500 |
219,196 |
409,642 |
| Ceesay Abraham | Chief Executive Officer |
Oct 15 '25 |
Sale |
25.81 |
5,833 |
150,541 |
579,579 |
| Ceesay Abraham | Chief Executive Officer |
Oct 15 '25 |
Sale |
25.81 |
5,083 |
131,189 |
41,061 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):